Learn About Retinopathy Pigmentary Mental Retardation
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
University Of North Carolina At Chapel Hill
Alessandro Iannaccone is an Ophthalmologist in Chapel Hill, North Carolina. Dr. Iannaccone is rated as an Elite provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, X-Linked Retinitis Pigmentosa (XLRP), and Usher Syndrome Type 2A. Dr. Iannaccone is currently accepting new patients.
UPMC Vision Institute
Jose' Sahel is an Ophthalmologist in Pittsburgh, Pennsylvania. Dr. Sahel is rated as an Elite provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Retinopathy Pigmentary Mental Retardation, X-Linked Congenital Stationary Night Blindness, Cone-Rod Dystrophy, Retinitis Pigmentosa, and Vitrectomy. Dr. Sahel is currently accepting new patients.
Hiroko Terasaki practices in Nagoya, Japan. Ms. Terasaki is rated as an Elite expert by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. Her top areas of expertise are Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, Retinal Vein Occlusion, Retinitis Pigmentosa, and Vitrectomy.
Summary: The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
Summary: This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (8.8M jCell) compared to sham-treated controls.